FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury
Traumatic brain injury (TBI) is a complex disease that leads to significant mortality and disability worldwide each year. TBI disrupts the normal activity of kinases and molecular signaling pathways, but the effective therapeutic methods for patients remain limited. Nowadays, kinase inhibitors appro...
Saved in:
Main Authors: | Dezhu Gao, Yu Shi, Zhiliang Wang, Weiming Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration
2024-12-01
|
Series: | Exploration of Drug Science |
Subjects: | |
Online Access: | https://www.explorationpub.com/uploads/Article/A100877/100877.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antioxidant and Anti-Inflammatory Properties of Melatonin in Secondary Traumatic Brain Injury
by: Mariusz Sieminski, et al.
Published: (2024-12-01) -
An analysis of referral patterns of traumatic brain injury at Groote Schuur Hospital Trauma Centre
by: N Parker, et al.
Published: (2024-07-01) -
Exploring Azithromycin’s Neuroprotective Role in Traumatic Brain Injury: Insights into Cognitive and Motor Recovery and Neuroinflammatory Modulation
by: Mohannad A. Almikhlafi, et al.
Published: (2025-01-01) -
Teaching Students with Disabilities: Traumatic Brain Injury
by: Sarah E. LaRose, et al.
Published: (2016-08-01) -
Teaching Students with Disabilities: Traumatic Brain Injury
by: Sarah E. LaRose, et al.
Published: (2016-08-01)